Alkermes Plc (ALKS) Stock Price
Alkermes Plc Price
Over the last 19 years Alkermes Plc grew revenue by 12.5% annually, reaching 1.56 B USD. Earnings per share have grown at 23.6% per year over the last 19 years. For Alkermes Plc, the net margin of 23.6% is up versus -10.7% a few years ago. The consensus 12-month price target for Alkermes Plc is 56.00 USD, about 38.3% above where the stock trades today. Of 25 analysts, 19 rate the stock a buy — an overall Buy consensus.
Alkermes Plc stock price
Alkermes Plc business model & stock analysis
Frequently asked questions about Alkermes Plc
The business model of Alkermes Plc is focused on the development and commercialization of innovative pharmaceutical products to address unmet medical needs. Alkermes is dedicated to providing solutions for patients through advanced drug delivery technologies, extensive research and development, and strategic partnerships. The company specializes in areas such as neuroscience, addiction medicine, and oncology, aiming to improve the lives of individuals suffering from a range of diseases and disorders. Alkermes Plc strives to create value for shareholders by delivering effective therapies while maintaining a strong commitment to scientific excellence and regulatory compliance.
Alkermes Plc is primarily active in the biopharmaceutical industry.
The main competitors of Alkermes Plc in the market are AstraZeneca, Johnson & Johnson, Novartis, and Pfizer.
Alkermes Plc is a pharmaceutical company with a rich history and strong background. Established in 1987, Alkermes has grown to become a leading biopharmaceutical firm specializing in the development and manufacturing of innovative medicines. The company is committed to making a difference in the lives of patients suffering from serious diseases, such as central nervous system (CNS) disorders and addiction. With a focus on research and development, Alkermes has successfully brought several FDA-approved therapies to market. By leveraging its expertise in drug delivery technologies, the company continues to advance its pipeline of potential treatments. Alkermes Plc is dedicated to improving health outcomes and reshaping the future of medicine.
Some significant milestones achieved by Alkermes Plc include the approval of VIVITROL for the prevention of opioid relapse, the launch of ARISTADA for the treatment of schizophrenia, and the acquisition of Elan Drug Technologies. Furthermore, the company also secured FDA approval for BYDUREON BCise, a once-weekly treatment for type 2 diabetes, and expanded its product portfolio through collaborations and partnerships. Alkermes Plc has consistently focused on developing innovative therapies and entering strategic alliances to address unmet medical needs, establishing itself as a leading biopharmaceutical company in the industry.
Alkermes Plc is primarily present in the United States.
Alkermes Plc is driven by a strong set of values and corporate philosophy. The company places emphasis on innovation, collaboration, and a patient-centered approach. Alkermes is committed to developing groundbreaking therapies and technologies to improve the lives of people with serious and complex medical conditions. With a focus on research excellence, they strive to bring forward solutions that address unmet medical needs. Alkermes values integrity, transparency, and accountability in all aspects of their work. By investing in their employees, fostering a diverse and inclusive culture, and engaging with stakeholders, Alkermes Plc aims to make a lasting positive impact in the healthcare industry.
Analysts currently set an average price target of 55.86 USD for the Alkermes Plc stock (median: 56.00 USD), implying +38.0 % versus the latest price. The consensus is based on 25 analyst ratings.
25 analysts currently rate the Alkermes Plc stock: 19 recommend buying, 5 holding and 1 selling. For 2026, analysts expect Alkermes Plc to generate revenue of 1.82 B USD and earnings per share of -0.53 USD.
Converted at the current exchange rate, the Alkermes Plc share trades at 36.12 EUR (40.48 USD).
The Alkermes Plc share (ALKS) is listed on 4 stock exchanges, including: NASDAQ (ALKS), SIX (Zürich) (8AK.SW), Frankfurt (8AK.F), München (8AK.MU).
Alkermes Plc is a leading company in the biopharmaceutical industry that specializes in researching, developing, and marketing drugs for the treatment of central nervous system disorders and addiction disorders. The company is headquartered in Dublin, Ireland and has global subsidiaries. The company divides its business activities into two segments: Commercial and R&D. The Commercial segment focuses on marketing drugs used for the treatment of addiction disorders such as alcohol dependence, opioid dependence, and smoking cessation. The R&D segment is dedicated to the discovery and development of drugs for the treatment of central nervous system disorders, including schizophrenia, depression, bipolar disorders, Alzheimer's, and multiple sclerosis. The company's key products include Vivitrol, Aristada, Risperdal Consta, and Ampyra. Vivitrol is the only long-acting medication approved by the US Food and Drug Administration (FDA) for treating both alcohol dependence and opioid dependence. Aristada is an injectable long-acting antipsychotic used for the treatment of schizophrenia. Risperdal Consta is a long-acting antipsychotic used for the treatment of schizophrenia and manic episodes in bipolar disorder. Ampyra is a potassium-optimized medication used for improved walking ability in patients with multiple sclerosis. In 2019, the company generated $1.17 billion in revenue. The majority of these earnings come from the sales of Vivitrol, Aristada, and Risperdal Consta. Additionally, Alkermes Plc has numerous partnerships with other companies to combine technology and research findings and develop new compounds. Overall, Alkermes Plc's business model is focused on developing and marketing innovative medications for the most common central nervous system disorders and addiction disorders. The company has a strong pipeline of product candidates focused on discovering and developing new therapies to improve clinical outcomes. Alkermes Plc has a strong market position and has the potential to further expand over time as it grows its global reach through partnerships and acquisitions.
The expected revenue of Alkermes Plc is 1.82 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Alkermes Plc is -89.41 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Alkermes Plc is currently -76.60. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Alkermes Plc stock.
The price-to-sales ratio (P/S) of Alkermes Plc is currently 3.76. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Alkermes Plc stock.
The Eulerpool Quality Score for Alkermes Plc is 6/10.
The ISIN of Alkermes Plc is IE00B56GVS15. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Alkermes Plc is A1JKVH. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Alkermes Plc is ALKS. The ticker symbol is used to trade Alkermes Plc shares on the stock exchange.
Alkermes Plc stock
Alkermes Plc Peer Group
Alkermes Plc Ticker
Alkermes Plc FIGI
All fundamentals and in-depth analysis of Alkermes Plc
Our stock analysis for Alkermes Plc stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Alkermes Plc. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.